跳至主要内容
临床试验/TCTR20220626001
TCTR20220626001尚未招募1 期

Efficacy and safety of acupuncture in the treatment of pain in patients with hepatocellular carcinoma: A protocol of a randomized, single-blind, placebo-controlled clinical trial

Zhilin Zhou0 个研究点目标入组 90 人开始时间: 2022年6月26日最近更新:

试验速览

阶段
1 期
状态
尚未招募
发起方
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 75 Years(—)
性别
All

入选标准

  • 1.Patients who are in accordance with the diagnosis of HCC (the diagnostic criteria refer to Guidelines for diagnosis and treatment of HCC (Version 2019)
  • 2. Aged: 18 to 75 years old, stable and conscious;
  • 3. Patients who have moderate and severe pain, and the 11-point numerical rating scale (NRS) score greater than 4
  • 4. Patients whose expected survival is greater than 6 months;
  • 5.Patients who have strong compliance and have signed informed consent.

排除标准

  • 1. Patients who are accompanied by infectious diseases, diseases of blood system;
  • 2. Patients who have history of acupuncture syncope;
  • 3. Women in pregnancy or lactation;
  • 4. Patients who have pain associated with causes other than HCC;
  • 5. Skin ulceration at the needling site.

研究者

发起方
Zhilin Zhou

相似试验

Efficacy and safety of acupuncture in the treatment... | 临床试验